Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This deal is a joke unfortunately. Coeptis has been established in October 2016. No sales forces, no track records, no balance sheets, no experienced management. If you search about this company on google you will find 0.
Consensi is one among lot of NSAIDs, how could you market it with this anonymous company? They will need lot of cash to do that, do they have some? I’m totally disappointed! But again the ceo here always been a red flag with his lack of experience.
I don’t like this deal at all but this link is totally not significant. Founder Mehalick (he was not ceo) is not been mentioned anywhere and probably he has been damaged by that ceo himself.
A little bit specious to say the least!
Turning the point to the deal, which I believe makes more sense, I think kitov needed a bigger and better company to market consensi.
The choice of this little company doesn’t make any sense to me.
Maybe with a different ceo. Long and hard way for Gil Efron that hopefully will bring some confidence again. Until then watch the horror movie of this incompetent ceo called Isaac Israel who left shareholders alone flirting with shorts.
Voted AGAINST ceo re-appointment. Good luck to all!
Voted AGAINST ceo re-appointment. Good luck to all!
Thanks for the updates!
15mm NSDAQ = 15mm TASE
(1:1 ratio)
It means that the Total O/S is 15mm
I will. Everyone should.
Not sure how to interpret this last news but I see three valid reasons for this R/S on TASE:
1. It lowers shares amount on TASE: from 300.000.000 to 15.000.000 and so it will be easier to pump (if any news will hit). Pretty sure most of Nasdaq pumps have been dropped by the “infinite” shares available on TASE;
2. It cleans the shares structure. Now there will be 15 million shares on TASE and 15 million shares on NASDAQ in 1:1 ratio. It will help traders to understand the total O/S (in fact most of the US site like finviz still don’t show the exact float/OS);
3. It will grant kitov to stay in some TASE indexes.
Yep so the ratio will be 1:1 and not 1:20 anymore. Nasdaq float will be the same of TASE float: approx 15 millions. Like it as well as it will be a low floater in Israel as well now.
Partnership will be signed. My guess is within year end.
Kitov Appoints Gil Efron as Deputy Chief Executive Officer and Chief Financial Officer
http://www.globenewswire.com/news-release/2018/10/11/1619923/0/en/Kitov-Appoints-Gil-Efron-as-Deputy-Chief-Executive-Officer-and-Chief-Financial-Officer.html
Maybe what Kitov needed?
He was deputy CEO and CFO of Kamada.
here from Kamada PR of September '17
http://www.kamada.com/news_item.php?ID=298
Kamada Ltd. (NASDAQ & TASE: KMDA) today announced that Gil Efron, Deputy Chief Executive Officer (Deputy CEO) & Chief Financial Officer (CFO) recently informed the Company of his plan to leave at the end of the year.
“Gil has played a key role in helping build Kamada into a leading international biopharmaceutical company,” said Amir London, Kamada’s CEO. “In his senior management position, he has been instrumental in multiple facets within the organization, including the development of the Company’s strategy, managing key processes and supporting critical corporate initiatives, such as expanding our agreements with Baxalta (now Shire), and guiding Kamada through its listing on the NASDAQ stock exchange in 2013 and our recent follow on public offering. We wish Gil all the best in his future endeavors.”
“After six years with Kamada, during which I took a leading role in the Company’s management, I believe it is time for me to move on and seek new senior management opportunities,” said Mr. Efron. “I am proud of what we have accomplished during my tenure at Kamada, including growing revenues from $34 million in 2010 to an expected $100 million and reaching profitability in 2017, as well as significantly improving the Company’s financial position.
Lol .... let’s hope the deputy ceo can help change the road took from current ceo. Kitov needs a change, it can’t be just Waymack. Israeli team need to wake up.
Agree with you .... lot of errors in that article. And he didn’t read well recent updates regarding legal matters.
Good summary of the possible catalysts in the coming weeks/months. Hopefully it will recover into the $2,5 range before any real news.
Don’t forget they mentioned partnership + launch in US and partnership in other territories. Wouldn’t be surprised if they were in talks we multiple interest parties all over the world .... after all we have an FDA-approved drug in the pipeline
That's a legit question.
Answers could be found here ....
"According to Dr. Waymack's filing, the SEC subpoena should be quashed because the SEC's assistance to the ISA in this matter would prejudice the public interest of the United States; that in conducting the underlying investigation, the ISA has violated both Israeli and United States law that would normally prohibit the ISA's conduct in certain matters in connection with the investigation; that Dr. Waymack's rights under American law as an American citizen and a respected member of the medical community would not be respected and preserved by the SEC providing assistance to the ISA; that to allow the SEC's subpoena to stand would result in an abuse of process; and, that the subpoena is also overly broad and unduly burdensome to both Dr. Waymack and Kitov".
But that's not all ... you can find ISA conduct here in the SEC filing ....
"He then most recently declined to produce documents or testify (i) because the ISA allegedly invaded his email account under a search warrant but in violation of United States law, (ii) because he is concerned that the ISA may use an adverse inference against him if he were to assert his right against self- incrimination before the Commission, (iii) because Kitov’s Israeli counsel is petitioning the ISA to change its investigation from a criminal investigation to an administrative investigation, and the ISA has not yet decided to act on that petition, and (iv) because the Israeli Attorney General has not yet responded to Kitov’s January 2018 letter to the Attorney General complaining about the invasion of certain Kitov-related email accounts".
Would you agree with him ???? i would ....
I fully support dr Waymack and Kitov. Two years of nothing for ISA and now asking SEC assistance.
Sec should not second them.
Sounds reasonable. Thanks for your input.
Sabby filed 13G not 13F .... are you sure Kitov should be listed there?
Thanks for sharing
Sure as it seemed FDA would have not approved, remember your posts? .... that kind of speculation doesn’t make any sense at this point.
Sad you are still sharing your ideas with haughtiness while you been proved wrong plenty of times.
Still wondering how could you be (or have been) long here.
First of all: Consensi™, is a combination for the simultaneous treatment of two clinical conditions: pain caused by osteoarthritis and hypertension (high blood pressure), which can be i. pre-existing or ii. caused by the treatment for osteoarthritis.
In the case sub i. and sub ii. This is translated in the best compliance as the pts will have to take just 1 pill instead of two.
Secondo let me show you these points:
“Consensi provides a solution to the concerns of physicians who avoid prescribing an NSAID treatment for pain caused by osteoarthritis due to its cardiovascular side effects and it reassures physicians who are concerned that their patients who are treated for osteoarthritis will also be treated for hypertension, which is a known side effect of NSAID treatments for pain caused by osteoarthritis. This is a particular concern, as hypertension is usually not accompanied by tangible symptoms, and therefore patients may not be aware of their condition or the need to treat it.
Furthermore, using one drug that also includes an active ingredient that treats hypertension either as an existing condition or as a side effect of using other drugs, ensures that the patient receives the suitable treatment for their disease and for its side effect”.
Last but not the least, per labeling this is the first NSAIDs that reduces HP collateral effects, reducing the risk of heart attacks. So if a physician (I don’t think you are one of them) should prescribe an NSAIDs this would be the safest one in terms of efficacy and safety considering that they proved that UNLIKE ADDING ANY NSAIDs TO AN HP DRUG, CONSENSI IS SAFE, EFFECTIVE AND NO TOXIC!
It looks like no near-term catalysts is hurting this stock. Hopefully we will have a surprise with a partnership announcement within September.
Kitov announces settlement!
https://globenewswire.com/news-release/2018/07/30/1543818/0/en/Kitov-Announces-Settlement-of-Shareholder-Class-Action-Litigation.html
All paid by insurers! Great job!
“The proposed settlement contains no admission of wrongdoing, and reiterates that Kitov has always maintained, and continues to believe, that it did not engage in any wrongdoing or otherwise commit any violation of federal or state securities laws or other laws, including, vigorous denials that the Company’s public statements were misleading; that it failed to disclose any material information from investors; or that it acted in any deceitful manner. Kitov has agreed to the proposed settlement on the basis of the advice and recommendations of its insurance carriers who are indemnifying Kitov for the expenses of conducting a defense in the Actions, as well as paying judgments which may be assessed as a result of the Actions. As such, Kitov believes that further litigation of the Actions would be protracted, burdensome, and expensive for Kitov as well as its insurers, and that it is desirable and beneficial that the claims asserted in the Actions be fully and finally settled and terminated in the manner of the proposed settlement, with no additional costs to Kitov”.
I sold some as well, still holding good amount and added some under 2$.
Good luck
Can’t count how many times he has been wrong and I would agree with you that this has been usually a great entry level. Sad it has revisited it again after approval (!!!) but as you said it usually happens after approval.
Hopefully is now time for a sustainable growth.
Good luck to us longs.
More probable the funds which have warrants at $1,5 are shorting it. Sabby and armistice have warrants at $2,8 (they can’t convert warrants to shares for covering until pps hits exercise price).
Obviously they can take advantage averaging down their long position.
Sorry but I can’t provide any link .... its on pacer.com .... it doesn’t cost too much but you can download all the legal documents.
The parties have agreed. Now it has to be validated by Judge but it’s just a formal step.
Very smart move by Management. Lawsuits could last years and cost millions. Settle for just $250K is the best way to go ahead and dont look back anymore to this baseless lawsuits. Now let’s sign the US deal! $KTOV
Looks like they found a settlement to resolve the claims of both actions (state and federal case) which will cost Kitov just $250k
From their last report .... and from recent Bloomberg article ....
Never been an easy hold for sure for us.
Waymack and his personal US team are great in science and experts in regulatory process with FDA but Management in Israel need to wake up and deliver a sustainable growth for ALL shareholders.
Lack of catalyst and maybe the funds which have ads/warrants at 1,5 and 1,875 are shorting it (not Sabby and armistice though).
Hopefully when They will cover it means us partnership has been signed.
Negotiations?
HCW gave Consensi $100mm valuation. I would agree with them.
500mm is unrealistic.
It went just down after conference call. Wondering if this was planned .... it looks like funds who recently bought the private offering are shorting it right now.
Very nice this could explode. Sad I didn’t load up big!!!!
I think there will be a settlement
I honestly fail to see how can someone buy or sell just reading these public forums and without doing his own DD.
Agree with selling Consensi at that price. Would be nice as well if they could find a partner that would allow them to generate enough revenues from US to fund NT219. I think Chinese one is very good. We wait.
Exactly but unfortunately in these public boards where everyone could sign and share his “idea” you will read the most baseless assumptions ever. This should be a place to share DD but it became a place where everyone can invent his personal fantasy movie .... lol
Lol rdhl .... doesn’t make any sense for them to partner consensi. Teva or Dexcel a concrete possibility. Still think it will be a US co. Though.
Would you have seen interest in vimovo ages ago? Bet not .... but they out licensed it to Horizon pharma. Do you see interest in consensi now? No .... but they will out license it.
In any case, consensi’s protections expires in 2029 .... so there you will be able to buy consensi generic version.
Insane that you are here since decades (we all remember your strange speculations about fda commission) and you still don’t know that consensi is not generic but is a patented combination ....